# Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

> **NCT00789698** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 240 (actual)

## Conditions studied

- Chronic Schizophrenia

## Interventions

- **DRUG:** Lurasidone HC1
- **DRUG:** Quetiapine XR

## Key facts

- **NCT ID:** NCT00789698
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789698, "Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00789698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*